[ad_1]
According to the complete results of the latest phase of the tests, the vaccine against covid-19 from the American biotech company Moderna is more than 94 percent effective, and has even prevented severe cases of the disease by one hundred percent.
The study showed no serious side effects. The company is now preparing to apply to US and EU regulatory authorities for emergency use approval of the substance.
The Moderna vaccine could be the second to be approved by US authorities this year, after Pfizer’s substance.
Pfizer applied to the US Food and Drug Administration (FDA) ten days ago.
They want to play a vital role
Independent consultants are expected to announce their recommendations to the FDA regarding the Pfizer vaccine on December 10, to meet the Moderna vaccine a week later.
“We think we have a very effective vaccine. We now have data to prove it.“said Tal Zaks, director of research. “We expect to play a vital role in transforming this pandemic for the better.” added.
In addition to the FDA, Moderna wants to apply for special permission from the European Medicines Agency (EMA), which has already started analyzing some data on its vaccine.
The efficiency figure announced today is four tenths of a percentage point lower than the value reported by the company in mid-November with reference to preliminary results. According to Zaksa, however, this is a statistically insignificant difference.
An advantage over Pfizer
Moderna has the advantage over Pfizer in that it does not need to be stored at extremely low temperatures and will therefore be easier to distribute to patients themselves. It does not lose its effectiveness even at temperatures that are in normal home freezers.
The company tested the vaccine on 30,000 people, some of whom only administered an inactive substance, called a placebo.
A total of 196 people became ill with Covidom-19 during the studies, 185 of whom were in the placebo group and the remaining 11 were vaccinated. Thirty people developed severe covid-19, but all were in the inactive group.
It prevents the severe form
The vaccine is therefore 100% effective in preventing a severe form of the disease, according to the company, which is true for gender, age and ethnicity.
The final results also showed no serious side effects of the substance. The most common were fatigue, vaccine site pain, or headache or muscle aches. However, all of these effects are only short-lived. For some people, the substance caused flu-like symptoms, but it didn’t endanger them in any way.
Moderna says it could have produced 20 million doses in the United States by the end of this year, which is enough to vaccinate 10 million people. Last week the European Commission approved an agreement with Moderna to purchase up to 160 million doses of the vaccine.
.
[ad_2]
Source link
